The authors presented the clinical experience from the first four patients with H3K27M-mutant diffuse intrinsic pontine glioma/diffuse midline glioma treated with GD2-CAR T cells at dose level 1.
[Nature]
Sorry, but the selected Zotpress account can't be found.
